A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

DiA Imaging Analysis Collaborates with Intel Corporation to Accelerate Processing Time of its AI-based Cardiac Ultrasound Software in Hospitals

DiA Imaging Analysis Collaborates with Intel Corporation to Accelerate Processing Time of its AI-based Cardiac Ultrasound Software in Hospitals

DiA Imaging Analysis Ltd, a leading global provider of AI-powered ultrasound analysis software, has teamed up with Intelto streamline artificial intelligence (AI) solutions used by echocardiography (Echo) labs. DiA’s AI-based software, LVivo Seamless™, automatically analyzes cardiac ultrasound images using the Intel® Distribution of OpenVINO™ toolkit, to optimize processing time by over 40% percent while maintaining accuracy.

The ability to view key cardiac measurements results quickly after each scan is vital to the Echo Lab workflow.

DiA Imaging Analysis LVivo Seamless™ algorithm runs automatically on cardiac ultrasound exams, selecting and analyzing the optimal cardiac views to generate key measurements that help identify clinical indications – that are otherwise difficult to find visually or manually. DiA’s solutions enable sonographers and cardiologists to analyze higher scan volumes in a quicker and reproducible way, optimizing their everyday workflows.

“Intel is committed to creating world-changing technology that helps advance patient care. Our edge-to-cloud infrastructure technology supports rich data analysis environments like DiA Imaging Analysis was able to optimize the processing time of its AI-based models by over 40% percent when running on local hospital IT infrastructure based on Intel CPUs, without requiring the use of a discrete graphics processing unit (GPU) or integration of more complex IT  infrastructures. LVivo Seamless, where time and accuracy are crucial elements,” said Alex Flores, Head of  Global Health Solutions at Intel Corporation.

By working with Intel, DiA Imaging Analysis was able to optimize the processing time of its AI-based models by over 40% percent when running on local hospital IT infrastructure based on Intel CPUs, without requiring the use of a discrete graphics processing unit (GPU) or integration of more complex IT  infrastructures.

“Every minute counts in a busy echocardiography environment. Using an AI solution like LVivo  Seamless that automatically runs ‘behind the scenes’ on hospital servers eliminates many manual and visual steps involved with both cardiac ultrasound view selection and measurement,” said Hila Goldman Aslan, CEO, and co-founder of DiA Imaging Analysis. “We are thrilled to work closely with Intel, leveraging AI to make the analysis of ultrasound images smarter, faster, and  more accessible.”


DiA Imaging Analysis is a leading provider of FDA-cleared and CE marked ultrasound AI  software solutions that automate the way clinicians use and analyze ultrasound scans. The company’s LVivo product line for cardiac and abdominal auto analysis allows clinicians with varying levels of ultrasound experience to automatically analyze ultrasound images on their ultrasound devices and healthcare IT systems with increased speed, efficiency, and accuracy.  DiA serves thousands of end-users worldwide.  

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy